Evidence map›Paper›PMID 35534362›Full record

ArticleEuropean annals of otorhinolaryngology, head and neck diseases2022

The first wave of COVID-19 did not cause longer wait times in head and neck cancer. Experience of a French expert center.

T Vanderhaegen, A Pierache, G Mortuaire, B Rysman, R Nicot, D Chevalier, F Mouawad

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European annals of otorhinolaryngology, head and neck diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

T VanderhaegenENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France.
A PieracheMETRICS: Evaluation des Technologies de Santé et des Pratiques Médicales - ULR 2694 - University Lille - CHU Lille, 59000 Lille, France.
G MortuaireENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France.
B RysmanENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France.
R NicotService de stomatologie et de chirurgie maxillo-faciale, hôpital Roger Salengro, université de Lille, CHU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France.
D ChevalierENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France; CANTHER "Cancer Heterogeneity, Plasticity and Resistance to Therapies", UMR9020 CNRS - U1277 Inserm - Université de Lille - CHU de Lille-COL, 59037 Lille cedex, France.
F MouawadENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France; CANTHER "Cancer Heterogeneity, Plasticity and Resistance to Therapies", UMR9020 CNRS - U1277 Inserm - Université de Lille - CHU de Lille-COL, 59037 Lille cedex, France. Electronic address: francois.mouawad@chru-lille.fr.
Centre Hospitalier Universitaire de Lille · FRCANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des CancersHôpital Claude Huriez · FRHôpital Roger Salengro · FRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck cancers (HNC) have poor survival prognosis, as tumors are often diagnosed at advanced stages in patients consulting late. The first lockdown linked to the 1st wave of COVID-19 (Coronavirus Disease 2019) disrupted consultation schedules in France.

objectiveThe principal aim of the present study was to analyze consultation wait time in HNC during and after lockdown, in our university expert oncology reference center, to disclose any increase in treatment wait time.

methodsA single-center retrospective study included patients with a first diagnosis of HNC. Three groups were distinguished: "lockdown", "post-lockdown", and a "control" group (corresponding to a reference period 1 year earlier). Intervals between first oncologic consultation and multidisciplinary tumor board (FC-MTB) and between MTB and first treatment (MTB-T) were assessed.

resultsOne hundred and seven patients were included in the control group, 60 in the lockdown group and 74 in the post-lockdown group. There was no increase in median FC-MTB interval (respectively 35, 29 and 28 days) between the lockdown and post-lockdown groups compared to the control group (respectively P=0.2298 and P=0.0153). Likewise, there was no increase in MTB-T interval (27, 20 and 26 days respectively) (P=0.4203).

conclusionNo increase in wait times was observed during the lockdown and post-lockdown periods in our center.

Indexed as

COVID-19Head and Neck NeoplasmsCommunicable Disease ControlHumansRetrospective StudiesSARS-CoV-2Waiting ListsCOVID-19Head and neck cancerMultidisciplinary tumor boardSARS-CoV-2Wait time

Identifiers

PMID35534362
PMCPMC9023346
OpenAlexW4224280015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.